To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Bill 119 HR 1117, also known as the Direct-to-Consumer Drug Advertising Restriction Act, aims to make changes to the Federal Food, Drug, and Cosmetic Act in order to limit the advertising of prescription drugs directly to consumers.

The bill proposes that pharmaceutical companies would no longer be allowed to advertise prescription drugs directly to consumers through mediums such as television, radio, print, and online advertisements. Instead, the focus would shift to healthcare providers who would be responsible for informing patients about prescription drug options.

Proponents of the bill argue that direct-to-consumer drug advertising can lead to unnecessary prescriptions, increased healthcare costs, and potential harm to patients who may not fully understand the risks and benefits of the medications being advertised. By restricting these advertisements, the bill aims to promote more informed decision-making by patients and reduce the influence of marketing tactics on prescribing practices. Opponents of the bill, however, argue that direct-to-consumer drug advertising plays a valuable role in educating patients about treatment options and empowering them to have informed discussions with their healthcare providers. They also raise concerns about potential limitations on free speech and the impact on pharmaceutical companies' ability to communicate important information about their products. Overall, Bill 119 HR 1117 represents a significant proposal to regulate the advertising practices of pharmaceutical companies and could have far-reaching implications for the healthcare industry. It is currently under consideration in the US Congress and will continue to be debated and discussed in the coming months.